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ABSTRACT 
 
The 5-hydroxytrptamine receptor 4 (5-HT4 receptor) is heavily expressed on 
colonic epithelial cells and has been targeted as a therapeutic for functional bowel 
symptoms and pain; however, adverse cardiac events related to 5-HT4 agonist treatment 
limited their therapeutic use. Previous studies in the Mawe laboratory have demonstrated 
that intraluminal application of a 5-HT4 agonist exerts protective epithelial actions in 
animal models of colitis, and accelerates recovery from colitis. The aim of this study was 
to test the effects of a luminally restricted 5-HT4 agonist in a mouse model of 
experimental colitis. 
The luminally restricted 5-HT4 agonist (Takeda Pharmaceuticals; 10 mg/kg) was 
administered to mice during active dextran sodium sulfate (DSS) induced colitis. Colitis 
activity was evaluated using disease activity index, a fecal lipocalin-2 assay, and 
histological damage scoring. Epithelial proliferation and colonic motility were also 
measured as readouts of the potential protective actions and colonic function, 
respectively. 
Oral gavage and intracolonic delivery of this luminally restricted 5-HT4 agonist 
had no detectable effect on recovery from colitis or colonic motility as compared to 
vehicle. Additionally, in positive control experiments, we failed to see an effect of the    
5-HT4 agonist, tegaserod, on colitis severity or colonic motility in any of the measures 
tested.  
In conclusion, it is unclear if the luminally restricted 5-HT4 agonist has any effect 
on recovery from DSS colitis. Given inconsistencies with the model and lack of an effect 
of tegaserod, additional studies will be required, possibly involving different doses and 
time points, to fully assess the actions of this luminally restricted compound in colitis 
recovery. 
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CHAPTER 1: LITERATURE REVIEW 
I. Structure and Organization of the Gastrointestinal Tract1 
A.   Organization of the Gastrointestinal Tract 
 The gastrointestinal (GI) tract is a long tube that begins in the mouth and ends at 
the anus. Each part of the GI tract is specialized to serve the overall function of the organ 
system, which is to breakdown ingested food into absorbable molecules, and to absorb 
those molecules for use as nutrients. While the GI tract has specialized parts, the basic 
structure of the gut wall is maintained throughout the length of the organ system. The 
four tissue layers of the gut are the mucosa, submucosa, muscularis externa and serosa. 
Additionally, the gut contains its own nervous system, the enteric nervous system, that is 
organized as several sets of ganglionated plexi, and that serve to coordinate the 
movements and functions of the gut. The myenteric (Auerbach’s) plexus is located within 
the muscularis externa and serves to control motor patterns, and the submucosal 
(Meissner’s) plexus is located within the submucosa and helps to coordinate secretion 
and vasodilation. The enteric nervous system is highly specialized and autonomous, 
receiving only moderate autonomic input from the central nervous system via the vagus 
nerve, sacral spinal roots S2-4, and prevertebral ganglia (celiac, superior and inferior 
mesenteric ganglia) within the abdominal cavity.  
 Starting from the mouth, food first enters the oral cavity and is mechanically 
broken down by mastication, and enzymatically by salivary amylase. From here, food is 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Information within this section is textbook material. See Silverthorn DJ, BR; Ober, WC; Garrison, CW; 
Silverthorn, AC (2013) Human Physiology: and Integrated Approach. Pearson. 
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swallowed and descends the esophagus via peristalsis, passes through the lower 
esophageal sphincter and enters the stomach. The stomach serves to temporarily store 
food, further digest food using acids, lipases and peptidases, and control the rate at which 
food enters the duodenum. Specialized parietal cells are responsible for maintaining the 
acidic environment of the stomach by secreting hydrochloric acid. The acidic 
environment of the stomach is important not only for helping to break down food 
particles, but also to kill any potential bacterial hazards. This acid, along with the other 
enzymes and mechanical movement, begin the process of digestion, primarily breaking 
down large food particles to create a soupy substance known as chyme. Chyme exits the 
stomach via the powerful pyloric sphincter and enters the duodenum.  
The duodenum is the first part of the small intestine and secretes alkaline mucus 
from Brunner’s glands to neutralize the acidic pH of the semi-solid chyme exiting the 
stomach. Two accessory GI organs, the pancreas and the gallbladder, secrete their 
contents into the duodenum at the ampulla of Vater. The entrance of these substances is 
controlled by the small circular muscle that surrounds the ampulla, called the sphincter of 
Oddi. The pancreas synthesizes many digestive enzymes, and the gallbladder stores and 
concentrates bile which contains enzymes to help break down fats. The distal two regions 
of the small intestine are the jejunum and ileum, respectively. Their border is ill-defined, 
but differences can be noted in the thickness of the mucosa. The jejunum has a thicker, 
more folded mucosa, while the ileum has a thinner mucosa and the presence of Peyer’s 
patches, seen as mounds under the epithelium. Peyer’s patches are nodes of lymphatic 
tissue contained within the submucosal layer of the gut, and play an important role in 
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maintaining gut homeostasis. The main function of the small intestine is to further break 
down food particles into nutrients and then readily absorb those nutrients into the 
bloodstream. The mucosa of the small intestine has specialized folds to increase surface 
area, including mucosal folds (plica circulares in the jejunum), villi (finger-like 
projections of mucosa), and microvilli (on the luminal side of individual epithelial cells). 
These specialized folds result in a 20-30 fold increase in surface area, resulting in more 
efficient nutrient absorption. Additionally, peristalsis and segmentation help to mix and 
mechanically break down food particles. Peristalsis is a coordinated motor pattern that 
helps push contents forward through the gut. Segmentation occurs to help mix intestinal 
contents with the digestive enzymes, and to ensure that all chyme contacts the absorptive 
mucosa. The small intestine empties into the cecum, which is located at the base of the 
ascending colon. The ileocecal valve prevents retrograde movement of intestinal contents 
back into the small intestine. 
 The large intestine is the final portion of the gastrointestinal system and serves to 
manage waste excretion and fluid balance. The large intestine consists of the cecum, 
colon and rectum. In humans, the large intestine can be divided in to four segments – the 
ascending colon, the transverse colon, the descending colon, and the sigmoid colon, 
which is directly followed by the rectum. In rodents, the colon has simply a distal and 
proximal part. The large intestine is noted for the prominent bands of longitudinal muscle 
running along the length of the colon called teniae coli. These bands of muscle are shorter 
than the length of the colon, which causes the colon to bunch. This bunching creates 
bulges called haustra. Additionally, the colon is histologically different than the small 
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intestine, containing no villi and instead having crypts of Lieberkühn, also called colonic 
glands. These glands contain predominately enteroctyes, but also contain more mucus 
secreting goblet cells than the small intestine. Specialized Enteroendocrine cells are 
generally located in the bottom third of the colonic glands. Finally, the rectum is the last 
portion of the GI tract and connects to the anus. It stores intestinal contents until time for 
defecation.  
 
B.   Tissues of the Gastrointestinal System 
The wall of the GI tract can be divided into three layers: the mucosa, the 
submusoca and the muscularis propria. Starting most centrally, the epithelium of the gut 
is in contact with the contents of the lumen. Deep to the epithelium lies the lamina 
propria. Deep to the lamina propria lies the muscularis mucosa and then the submucosa. 
The submucosal ganglia are located within the submucosal space. Outside of the 
submucosa sits the muscularis propria which contains a layer of longitudinal and a layer 
of circular muscle, with the myenteric nerve plexus sitting in between.  
 
1.   Mucosa 
 The mucosal layer of the GI tract is comprised of three sublayers – the epithelium, 
lamina propria and muscularis mucosa. The epithelial layer is a heterogeneous mix of cell 
types, including enterocytes, Paneth cells, enteroendocrine cells, and goblet cells, with 
the latter two only present in the stomach and intestines. These cells have specialized 
functions and help to both protect the tissue, and maintain barrier function. The epithelial 
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layer in the oral cavity, pharynx, and esophagus is made of non-keratinized, stratified 
squamous epithelium, whereas the stomach and intestines contain simple columnar 
epithelium. Additionally, the epithelium of the stomach and intestines is organized into 
tubular glands, or folds. These folds help to not only increase surface area for nutrient 
absorption in the small intestine (plicae circulares), but also allow for expansion of the 
stomach to accommodate food intake (rugae), and restrict the movement of intestinal 
contents within the colon. The lamina propria is a layer of loose connective tissue that 
provides vascularization to the epithelium and houses mucosal glands and gut associated 
lymphoid tissues, including B and T lymphocytes and dendritic cells. Together, the 
epithelium and the immune cells in the lamina propria work to maintain barrier function 
and homeostasis within the gut. Lastly, the muscularis mucosa is a thin muscular layer 
beneath the lamina propria that modulates the surface area of the lumen. Contraction 
causes the rugae of the stomach and plicae circulares of the small intestine to decrease the 
available surface area, whereas relaxation of the muscularis mucosa causes those 
structures to expand, increasing the available surface area. 
 
2.   Submucosa 
The submucosa is a rich connective tissue layer that houses the submucosal 
plexus of the enteric nervous system. In some areas of the gut, such as the duodenum, this 
layer contains glands that secrete contents into the lumen to aid in the digestive process. 
This layer is also rich in blood vessels and lymphatics. The submucosal plexus is 
responsible for coordinating secretory reflexes, as well as vasodilatory reflexes.  
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3.   Muscularis Externa 
The muscularis externa is comprised of two muscular layers and one ganglionated 
plexus. The myenteric plexus is sandwiched between a layer of circular muscle and a 
layer of longitudinal muscle. These two layers of muscle contract and relax in a 
coordinated fashion to produce motor patterns within the gut, including segmentation and 
peristalsis. Segmentation occurs when adjacent sections of gut contract and relax in a 
coordinated manner to allow for mixing of luminal contents. Peristalsis causes the 
forward movement of luminal contents by an upstream contraction and a downstream 
relaxation. These motor patterns are coordinated primarily by the myenteric plexus, with 
little extrinsic input from the central nervous system. 
 
4.   Serosa 
The serosa, or adventitia layer, is a sheet like membrane covering the outside of the 
gut, and is made of a single layer of mesothelial cells. The parts of the GI tract that are 
intraperitoneal are covered with serosa, while the retroperitoneal parts, the esophagus, 
and the oral cavity are covered in adventitia. The serosa and the adventitia layer both 
serve the role of providing an external layer of tissue to these organs. The serosa is 
continuous with the visceral peritoneum lining the abdominal cavity. It contains blood 
vessels, lymphatics and nerves, and, within the intraperitoneal space, is connected to the 
mesentery.  
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II. Serotonin 
	  
A.   History  
 The substance now known as serotonin was first isolated from rabbit gastric 
mucosa by the Italian pharmacologist Vittorio Erspamer in 1937 (Erspamer V, 1937). He 
named this bioactive amine, enteramine, as he identified it in the GI tracts of almost 
every vertebrate he studied. Later, a compound with vasoconstrictive properties was 
identified in bovine serum by researchers at the Cleveland Clinic. Maurice Rapport, Arda 
Green and Irvine Page called this compound serotonin due to its effect increasing 
vascular tone (Rapport et al., 1948). In time, these two molecules were discovered to be 
the same, 5-hydroxytryptamine, and the name serotonin was adopted for general use.  
 
B.   Gastrointestinal Mucosal Serotonin  
Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule for 
many physiological systems, and it plays a particularly crucial role within the GI tract 
(Mawe and Hoffman, 2013). The mucosa of the GI tract contains the body’s largest store 
of 5-HT. It is synthesized from tryptophan, using the enzyme tryptophan hydroxylase-1 
(TPH-1), by enterochromaffin (EC) cells within the gut epithelium. Once synthesized it is 
stored in intracellular granules along the basal side of EC cells until released into the 
lamina propria. Release can be stimulated by intraluminal changes in acidity, pressure, or 
increased nutrient concentration. Once within the lamina propria, 5-HT interacts with a 
variety of cell types, including enteric neurons, extrinsic neuron projections, epithelial 
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cells and immune cells. The precise action of 5-HT depends on the type of receptor that is 
expressed.  
To terminate 5-HT signaling, molecules are removed from the extracellular space 
via the serotonin-selective reuptake transporter (SERT) protein. SERT is expressed on 
serotonergic enteric neurons and virtually all intestinal epithelial cells. Once 5-HT has 
been transported into cells by SERT, it is either degraded by intracellular degradative 
enzymes, such as monoamine oxidases, or is repackaged into vesicles. Any 5-HT not 
transported out of the interstitial space will enter the blood stream via the dense capillary 
bed in the lamina propria, and be taken up by blood platelets, which also express SERT.  
 Altered serotonin signaling within the GI tract is implicated in human 
inflammatory bowel diseases (IBD) such as Crohn’s Disease and Ulcerative Colitis. 
Changes in GI serotonin content, EC cell density and SERT expression have been 
reported in both human disease and animal models of colitis (Coates et al., 2017). It is 
also known that serotonin can modify GI motility and that activation of epithelial 
serotonin receptors has protective epithelial actions and promotes recovery from colitis 
(Hoffman et al., 2012, Spohn et al., 2016). It should also be noted that serotonin exerts 
pro-inflammatory actions in the GI tract through activation of 5-HT7 receptors on 
dendritic cells (Spohn and Mawe, 2017). 
 
C.   5-HT4 Receptor  
 There are seven classes of 5-HT receptors (5-HT1 – 5-HT7), with 13 distinct 
subtypes, 7 of which are expressed in the GI tracts of humans (5-HT1A, 5-HT2A, 5-HT2B, 
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5-HT3, 5-HT4, and 5-HT7)(Mawe and Hoffman, 2013). They have been identified on a 
variety of cell types within the gut, including enterocytes, goblet cells, EC cells, neurons, 
immune cells, smooth muscle cells and interstitial cells of Cajal. One receptor subtype, 
the 5-HT4 receptor, plays an important role in gastrointestinal homeostasis and motility. 
The 5-HT4 receptor is a G-protein coupled receptor, that is Gs coupled and activates the 
adenylate cyclase/cyclic adenosinemonophosphate (cAMP)/protein kinase A pathway. 
Thus, it plays a role in many different cellular functions including, but not limited to, 
prosecretory actions and facilitation of neurotransmitter release (Tonini et al., 1989, Pan 
and Galligan, 1994, Hoffman et al., 2012) 
 The 5-HT4 receptor is expressed on enteric nerve terminals, where it helps to 
mediate neurotransmitter release through presynaptic facilitation (Pan and Galligan, 
1994). It has also been demonstrated that 5-HT4 receptor stimulation promotes enteric 
neuronal survival and neurogenesis (Liu et al., 2009). This receptor is also heavily 
expressed on colonic epithelial cells, where it helps to mediate 5-HT release from 
enterochromaffin cells, stimulates chloride secretion from enterocytes, and promotes 
goblet cell degranulation (Hoffman et al., 2012). Furthermore, activation of epithelial 5-
HT4 receptors has been shown to stimulate propulsive motility, decrease visceral 
hypersensitivity, promote epithelial proliferation and promote the integrity of the 
epithelial barrier (Spohn et al., 2016).  
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D.   Mucosal 5-HT4 Receptor Actions 
There is strong evidence for mucosal 5-HT4 receptors mediating the prokinetic, 
anti-nociceptive and anti-inflammatory actions within the gastrointestinal tract. The 5-
HT4 receptor is specifically expressed by a multitude of cells types in the epithelium of 
the GI tract, including 5-HT containing enterochromaffin (EC) cells, mucin-2 containing 
goblet cells and enterocytes in human and mouse tissues (Hoffman et al., 2012, Spohn et 
al., 2016) 
 
1.   Prokinetic Actions 
5-HT4 agonists have potent prokinetic actions that have been identified through 
multiple mechanisms and at multiple sites of action. Our lab previously reported that 
activation of EC cells with a 5-HT4 agonist results in an increased release of 5-HT and 
increases in goblet cell cavitation and mucus release (Hoffman et al., 2012). It has also 
been shown that stimulation of the cAMP/PKA pathway in human colonic cell lines 
results in mucus secretion (Bradbury, 2000). This implies that mucus release could result 
from direct activation of mucosal 5-HT4 receptors. Lastly, it is known that 5-HT increases 
chloride secretion in GI epithelium and that application of 5-HT4 agonists to mouse 
colonic tissue increases the ISC current (Budhoo et al., 1996, Ning et al., 2004, Hoffman 
et al., 2012). Together, these three actions of 5-HT4R activation may contribute to 
increasing propulsive motility of the GI tract in the following ways: (1) Increases in 5-HT 
release can directly activate peristaltic reflex circuitry; (2) Increases in mucus secretion 
may help decrease intraluminal friction, easing the passage of luminal contents; and (3) 
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Increases in chloride secretion result in increased water content in the lumen, softening 
stool and allowing for ease of passage. Furthermore, 5-HT4 agonists have been shown to 
directly increase colonic motility in healthy and inflamed colons of guinea pig and mice 
by directly activating peristaltic reflex circuitry (Grider et al., 1998, Jin et al., 1999, 
Spohn et al., 2016). Together, these results indicate a potent prokinetic effect of 5-HT4 
receptor activation. 
 
2.   Anti-nociceptive Actions 
Anti-nociceptive effects of 5-HT4 agonists have been observed in rat models of 
hypersensitivity and in clinical trials in humans. The 5-HT4 agonist tegaserod alleviates 
abdominal pain and discomfort in rats, as seen by a decrease in colonic hypersensitivity 
(Greenwood-Van Meerveld et al., 2006, Hoffman et al., 2012). Greenwood-Van 
Meerveld and colleagues demonstrated that rats with both acute and chronic 
hypersensitivity showed a decreased visceral motor response to colorectal distention after 
oral or intracolonic treatment with tegaserod. The response to intracolonically delivered 
tegaserod was blocked by pretreatment with the 5-HT4 selective antagonist GR113808. 
Multiple clinical trials have reported a significant decrease in perceived abdominal pain, 
a decrease in straining and an improvement in stool consistency for IBS patients treated 
with tegaserod as compared to control patients (Novick et al., 2002, Chey et al., 2008). 
The exact mechanism by which 5-HT4 activation alters visceral hypersensitivity is 
unknown.  
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3.   Protective Epithelial Actions 
Our lab has demonstrated the protective actions of mucosal 5-HT4 receptors in a 
multitude of animal models and assays. Intracolonic tegaserod treatment decreased 
clinical and histological damage scores in both the 2,4,6-trinitrobenzine sulfonic acid 
(TNBS)(mouse and guinea pig) and dextran sodium sulfate (DSS)(mouse) models of 
colitis (Spohn et al., 2016). Intraperitoneal administration of a 5-HT4 agonist did not 
provide a protective effect, and the protective and restorative effects of intracolonic 
treatment were blocked by antagonist treatment (Spohn et al., 2016). In addition, these 
effects were not present in 5-HT4 deficient mice. These results suggest that activation of 
the 5HT4 receptor is sufficient to induce a protective response in experimental colitis. 
Furthermore, tegaserod treatment in mice with DSS colitis improved epithelial barrier 
function as seen by a decrease in bacterial translocation to the spleen or liver (Spohn et 
al., 2016). Lastly, treatment of Caco-2 cells, a human epithelial colorectal 
adenocarcinoma cell line, with tegaserod resulted in increased resistance to oxidative 
stress, and an increased rate of cell migration following an in vitro scratch assay (Spohn 
et al., 2016). These results were blocked by antagonist treatment. Together, these actions 
suggest a potent protective effect of epithelial 5-HT4 receptor activation in vivo and in 
vitro.  
 
E.   Epithelial 5-HT4 receptors as a therapeutic target 
The 5-HT4 receptor has been identified as a potent therapeutic target for 
constipation relief in irritable bowel syndrome (IBS) and chronic constipation, as well as 
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pain relief in IBS; however, off-target cardiac effects have limited their use in clinical 
populations (Novick et al., 2002, Chey et al., 2008, Tack et al., 2012). 
Agonists of the 5-HT4R, including cisapride and tegaserod, have had remarkable 
clinical success for patients with constipation and constipation predominant IBD; 
however, their use in patient populations was suspended or restricted after reports of 
adverse cardiovascular events (McCallum et al., 1988, Evans et al., 2007, Tack et al., 
2012).  
Tegaserod was removed from the market in 2007 by recommendation from the 
FDA based on evidence from pooled clinical trial data suggesting a risk of ischemic 
cardiovascular events (Wooltorton, 2004). However, it is unknown how tegaserod led to 
these adverse events. Tegaserod has a low affinity for the 5-HT1B receptor located on 
blood vessels, but causes vasodilation, and thus would not lead to ischemia. A large, 
matched-cohort study in 2010 detected no increase in ischemic cardiovascular events in 
tegaserod users (Loughlin et al., 2010). 
 Cisapride is a benzamide, with moderate affinity and poor selectivity for the 5-
HT4 receptor (Nagakura et al., 1999). It also blocks 5-HT2, 5-HT3, and the human ether-
a-go-go-related gene (hERG)- encoded K+ channel (Nagakura et al., 1999, Potet et al., 
2001). The hERG channel is present on cardiac smooth muscle cells, and it is thought 
that blockage of this channel led to a lengthening of the QT interval, causing the adverse 
cardiac events, particularly in individuals with long QT syndrome (Drolet et al., 1998). 
While 5-HT4 agonists other than cisapride have shown to have low to no-binding 
capacity for the hERG-K+ channel, or other K+ or Na2+ channels, there is still a stigma 
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and fear associated with serotonin receptor agonists as a therapeutic target (Tack et al., 
2012). Since these side effects were a result of systemic availability, a therapeutic in 
which the active compound is not absorbed systemically could yield the same efficacy 
without the potential for dangerous off-target effects.  
 
II. Inflammatory Bowel Disease 
	  
Inflammatory Bowel Disease (IBD) is a condition of chronic or relapsing/remitting 
inflammation of the gastrointestinal tract. IBD is an umbrella term that includes Crohn’s 
disease (CD) and Ulcerative Colitis (UC). This disease typically manifests between the 
second and third decade of life, and predominately affects women over men. According 
to the CDC, in 2015 the prevalence of IBD diagnosis was 1.3% (3.1 million) of U.S. 
adults, which increased from 0.9% (1.8 million) in 1999. This study showed a higher 
prevalence in adults over the age of 45, Hispanics, non-Hispanic whites, and adults with a 
less than high school education (Dahlhamer, 2016). However, other studies have shown 
increased prevalence at higher socioeconomic levels (Krishnan and Korzenik, 2002).  
There is extensive physical and financial burden on those suffering from IBD. 
According to a 2008 study, the average annual cost for those suffering from IBD is 
between $5000 and $10,000 (Kappelman et al., 2008). Additionally, there is a higher 
hospitalization rate for individuals with IBD, and most patients will require surgery at 
least once in their lifetime (Bewtra et al., 2007). There is no current cure of IBD, only 
life-long palliative treatments. 
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The etiology of IBD is unknown. It is thought that a combination of altered gut 
microbiota and aberrant mucosal immune responses due to diet and environmental factors 
in genetically susceptible individuals leads to development of IBD (Matsuoka et al., 
2018). There have been 163 susceptibility loci identified for IBD, including 
approximately 300 potential genes (Loddo and Romano, 2015). The first IBD associated 
gene discovered was for nucleotide-binding oligomerization domain containing 2 
(NOD2), which codes for an intracellular pattern recognition receptor. Bacterial binding 
to this protein induces autophagy in dendritic cells, and mutations in this protein are 
associated with CD (Cooney et al., 2010). There is a prominent familial component to 
IBD, with relatives of CD or UC having an 8- to 10-fold greater risk for developing IBD, 
and there is concordance between twins (Cho and Brant, 2011). The immunopathogenesis 
of IBD is still being elucidated, and is vastly complex. Simply, it appears that CD is 
primarily TH1 mediated and UC is primarily TH2 mediated; however, there is significant 
overlap in their immunologic profiles (Wallace et al., 2014). CD and UC share 
overlapping etiologies, but they differ anatomically and histologically, as described 
below. 
 
A.   Crohn’s Disease 
Crohn’s disease (CD) can affect any part of the gastrointestinal tract, but 
commonly affects the distal small intestine, and the proximal colon. It is characterized 
by discontinuously affected areas of inflammation, transmural immune cell 
infiltration and fistulas. The major symptoms of Crohn’s include diarrhea, abdominal 
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pain, weight loss, fever, and less frequently bloody or mucus covered stool. 
Genetically, CD is primarily associated with genes for lymphocyte chemotaxis and 
trafficking genes (Franke et al., 2010).  
 
B.   Ulcerative Colitis 
Ulcerative colitis (UC) most prominently affects the colon, primarily the distal 
side, and has a continuous area of inflammation. Histologically, the inflammation 
only affects the mucosal layer, leaving the deeper layers of the gut unaffected, and 
often forms erosions. The major symptoms of UC include recurrent bloody diarrhea, 
abdominal pain and frequent bowel movements. Genetically, UC is associated with 
genes that regulate barrier function, including proteins involved in epithelial tight 
junction integrity (Anderson et al., 2011). UC is also associated with an increased risk 
in colon cancer.  
 
C.   Current Therapies  
The predominant current therapies for IBD include anti-inflammatory, 
immunosuppressive, and biologic therapies (Neurath, 2017). Anti-inflammatory drugs 
include 5-aminosalicylates (5-ASAs) and corticosteroids. While both are effective at 
inducing remission, only 5-ASAs help to maintain remission. Immunosuppressive 
therapies, including azathioprine, methotrexate and circlosporin-A, have efficacy 
inducing and maintaining remission of both CD and UC. Lastly, biologic therapies, 
including monoclonal antibodies that target tumor necrosis factor (TNF)-alpha 
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(infliximab, adalimumab, golimumab and certolizumab pegol), have been used to 
induce and maintain remission in UC and CD. Studies have shown that combined 
immunosuppressive and biologic therapies are more effective at inducing and 
maintaining remission than either therapy alone for both UC and CD (Colombel et al., 
2010, Panaccione et al., 2014).  
Given the complex etiology and the varied cytokine profiles of IBD patients, it is 
challenging to find the appropriate therapeutic for a given individual. Approximately 
30-50% of patients do not respond to anti-TNF agents, and there is a significant risk 
of relapse after discontinuation of anti-TNF therapy (40% in CD and 28% in UC) 
(Olesen et al., 2016, Neurath, 2017). To fill this void, many new therapeutic targets 
are currently being studied, including integrin blockers and modulators of T-cell 
trafficking (alpha-4beta-7, beta-7, MAdCAM1, and S1P receptor agonists), matrix 
metalloprotease inhibitors to mediate fibrosis and tissue remodeling (MMP 9 
inhibitors CHST15 siRNAs), blockers of transcription factors and modulators of 
barrier function and anti-inflammatory pathways (Neurath, 2017).  
The therapies described above are useful, but up to 40% of patients still 
experience other functional bowel symptoms, even when the disease is in remission 
(Coates et al., 2013, Vivinus-Nebot et al., 2014). These functional bowel symptoms 
include abdominal pain and changes in bowel habits that, while not inherently 
dangerous, severely affect the patient’s quality of life. Traditional therapies are 
targeted at dampening the immunological component of IBD; however, there is a 
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clear need for novel therapies targeting these functional bowel symptoms experienced 
by most patients.   
 
	  
III. Animal Models of Colitis 
	  
There is no perfect animal model that recapitulates all features of human 
inflammatory bowel disease; however, there are a few different models that have key 
features of IBD. These models include the chemically induced models: dextran sodium 
sulfate, TNBS, and oxazolone; and spontaneous colitis in interleukin(IL)-10 deficient 
mice (Kiesler et al., 2015, Wirtz et al., 2017). These methods all reproduce histological, 
pathological and immunologic hallmarks of inflammatory bowel diseases, the details of 
which are described below: 
 
A.   Dextran Sodium Sulfate 
DSS colitis is induced by oral administration of the sulfated polysaccharide 
dextran sodium sulfate. This experimental colitis recapitulates the clinical and 
inflammatory features of ulcerative colitis (Okayasu et al., 1990). The exact 
mechanism is not entirely understood, but it is thought that the molecule is taken up 
into epithelial cells, altering tight junction proteins, and leading to compromised 
barrier function. The increased epithelial permeability allows luminal bacteria and 
their by-products to interact with mucosal and submucosal immune cells, resulting in 
rapid and intense inflammation. It has been hypothesized that DSS creates nano-
lipocomplexes with fatty acids that fuse to the membranes of epithelial cells, and 
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penetrate the cell membrane, depositing DSS molecules intracellularly, thus affecting 
barrier permeability (Laroui et al., 2012). These changes in barrier function are likely 
due to alteration in tight junction protein expression. It has been shown that DSS can 
alter ribosome interactions (Miyazawa et al., 1967). Furthermore, it is known that the 
cytokines IL-1b and IL-18 play crucial roles in the development of DSS colitis, and 
that the NLRP3 inflammasome is necessary for DSS colitis to develop, indicating a 
role for the innate immune system (Bauer, 2010). Additionally, immune deficient 
mice are susceptible to DSS, showing that the adaptive immune system is not 
required for this immune response (Dieleman et al., 1994); however, TH1 and TH2 
cytokines are present in experimental models of chronic colitis (Dieleman et al., 
1998). DSS induced colitis is an acceptable model to study the features of ulcerative 
colitis, particularly impaired barrier function. 
  
B.   Trinitrobenzine Sulfonic Acid 
TNBS is a haptenizing agent that is administered intracolonically with ethanol. 
The ethanol allows the TNBS to access the epithelial cells and penetrate the gut wall. 
TNBS colitis predominately recapitulates the features of CD, including infiltration of 
CD4+ T-cells and neutrophils, transmural inflammation, spontaneous resolution of 
inflammation, fibrosis of the mucosal tissue, severe diarrhea, weight loss and rectal 
prolapse (Neurath et al., 1995, Kiesler et al., 2015). Additionally, TNBS colitis and 
CD are both characterized by a TH1 and TH17 CD4+ T-cell dominant response, 
involving cytokines IFN-g and IL-17 (Strober and Fuss, 2011).  
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This experimental colitis model has been particularly useful in studying the role 
of the adaptive immune system and T cell responses in inflammatory bowel disease. 
However, the role of the innate immune system should not be understated, as immune 
deficient mice are still susceptible to TNBS administration (Fiorucci et al., 2002). 
This is because IL-12 production by innate cells is necessary to drive the T-cell 
response.   
 
C.   Other Models of IBD: IL-10 knockout and Oxazolone colitis  
Interleukin-10 knockout mice spontaneously develop colitis between 4 and 8 
weeks of age, with inflammation featuring infiltration of lymphocytes, macrophages 
and neutrophils into the intestinal mucosa (Kuhn et al., 1993). This model has been 
useful for assessing immunoregulation and macrophage involvement in gut 
homeostasis. The inflammatory response in IL-10-/- mice is initially driven by TH1 
cells and related cytokines; however, this response slowly subsides and a TH2, IL-4 
and IL-13 driven response becomes the dominant profile (Spencer et al., 2002). This 
phenomenon gives insight into the dynamic changes in immunoregulation occurring 
in gut inflammation that may parallel human IBD.  
Oxazolone is another haptenizing agent that, when applied intracolonically 
induces colonic inflammation. The features of oxazolone colitis align with features of 
UC both morphologically and immunopathologically. It causes superficial 
inflammation of the mucosa within the distal colon, including infiltration of 
lymphocytes and neutrophils, and erosions (Boirivant et al., 1998). It is characterized 
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by a TH2 cytokine profile, including IL-13 secretion from CD4+ natural killer T cells 
in the lamina propria (Heller et al., 2002). IL-13 is known to cause and increase 
epithelial cell apoptosis, an increase in the pore-forming tight junction protein 
claudin-2, a decrease in the tight junction protein tricellulin and ultimately decreased 
barrier function (Heller et al., 2005, Krug et al., 2017). This model is useful for 
studying the immunopathogenesis of UC. 
 
IV. Specific Aims 
	  
Serotonin is a very important signaling molecule within the gastrointestinal (GI) tract. 
One receptor subtype, the 5-HT4 receptor, has been identified as a potent therapeutic 
target for functional bowel disease and pain. Agonists of the 5-HT4 receptor, including 
cisapride and tegaserod, have had remarkable clinical success as prokinetic agents; 
however, adverse side effects due to systemic availability led to their removal from the 
market. Our lab has recently discovered that 5-HT4 receptors are highly expressed in the 
colonic epithelium, and that activation of these receptors promotes motility and induces 
protective epithelial actions (Hoffman et al., 2012, Spohn et al., 2016). We hypothesize 
that the administration of luminally restricted 5-HT4 agonists will accelerate recovery 
from established colitis by inducing protective epithelial actions and restoring normal 
motility patterns.  
Aim 1: Evaluate the effect of luminally restricted 5-HT4 agonists on disease severity 
in DSS colitis. Hypothesis: Administration of luminally restricted 5HT4 agonists by 
enema will exert protective epithelial actions in the murine model of DSS induced colitis. 
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A recovery paradigm will be used to test this hypothesis. The recovery paradigm will test 
whether 5-HT4 agonist treatment, initiated after DSS colitis is established, accelerates 
recovery from colitis. Outcome measures will include daily recordings of disease activity 
index, fecal lipocalin-2 levels, analysis of epithelial proliferation, and histological 
damage scores.   
Aim 2: Evaluate the effect of luminally restricted 5-HT4 agonists on colonic motility 
in DSS colitis. Hypothesis: Application of a luminally restricted 5-HT4 agonist will 
increase colonic motility in vivo. This hypothesis will be tested using in vivo techniques 
to elucidate functional outcomes of the luminally restricted agonist. Two assays will be 
used to assess gastrointestinal function in DSS mice treated with the non-absorbable 5-
HT4 agonist: colonic motility and fecal output and consistency. These assays will be 
performed throughout the DSS recovery paradigm.  
 The proposed studies are designed to elucidate the effects of luminally restricted 
5-HT4 agonists on development of and recovery from colitis. We will use well validated 
in vivo assays to determine the protective epithelial actions of this compound on the 
gastrointestinal tract. These studies will examine the therapeutic potential of luminally 
restricted 5-HT4 agonists for the treatment of IBD.  
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CHAPTER II: PROTECTIVE ACTIONS OF LUMINALLY RESTRICTED 5-HT4 
RECEPTOR AGONISTS IN DEXTRAN SODIUM SULFATE INDUCED 
COLITIS 
	  
I. Abstract 
Background: The 5-hydroxytrptamine receptor 4 (5-HT4 receptor) is heavily expressed 
on colonic epithelial cells and has been targeted as a therapeutic for functional bowel 
symptoms and pain; however, adverse cardiac events related to 5-HT4 agonist treatment 
limited their therapeutic use. Previous studies in the Mawe laboratory have demonstrated 
that intraluminal application of a 5-HT4 agonist exerts protective epithelial actions in 
animal models of colitis, and accelerates recovery from colitis. The aim of this study was 
to test the effects of a luminally restricted 5-HT4 agonist in a mouse model of 
experimental colitis. 
Methods: The luminally restricted 5-HT4 agonist SYR313832Z (Takeda 
Pharmaceuticals; 10 mg/kg) was administered to mice during active DSS colitis. Colitis 
activity was evaluated using disease activity index, a fecal lipocalin-2 assay, and 
histological damage scoring. Epithelial proliferation and colonic motility were also 
measured as readouts of the potential protective actions and colonic function, 
respectively. 
Results: Oral gavage and intracolonic delivery of SYR313832Z had no detectable effect 
on recovery from colitis or colonic motility as compared to vehicle. Additionally, in 
positive control experiments, we failed to see an effect of the 5-HT4R agonist, tegaserod, 
on colitis severity or colonic motility in any of the measures tested.  
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Conclusions: In conclusion, it is unclear if the luminally restricted 5-HT4 agonist 
SYR313832Z has any effect on recovery from DSS colitis. Given inconsistencies with 
the model and lack of an effect of tegaserod, additional studies will be required, possibly 
involving different doses and time points, to fully assess the actions of SYR313832Z in 
colitis recovery.  
 
II. Introduction 
Serotonin (5-hydroxytryptamine, 5-HT) is an important signaling molecule for 
many physiological systems, and it plays a particularly crucial role within the 
gastrointestinal (GI) tract. Within the GI tract, 5-HT acts as a neurotransmitter and 
paracrine signaling molecule to stimulate motility, secretion, vasodilation and sensation 
(Mawe and Hoffman, 2013). Altered serotonin signaling within the GI tract is implicated 
in human inflammatory bowel diseases (IBD), such as Crohn’s Disease and Ulcerative 
Colitis (Coates et al., 2017). Serotonin receptors have been the target of therapies for 
functional gastrointestinal disorders and pain (Mawe and Hoffman, 2013). Unfortunately, 
use of many of these therapies was suspended or restricted due to reports of adverse 
cardiovascular events (De Maeyer et al., 2008).   
Serotonin exerts its effects through activation of a family of G-protein coupled 
receptors. One receptor, the 5-HT4 receptor, is a G-protein coupled receptor, that is Gs 
coupled and activates the adenylate cyclase/cyclic adenosine monophosphate 
(cAMP)/protein kinase A pathway. The 5-HT4 receptor, is expressed on enteric nerve 
terminals, where it helps to mediate neurotransmitter release through presynaptic 
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facilitation, and is amply expressed on colonic epithelial cells, where it mediates 5-HT 
release from enterochromaffin cells, stimulates chloride secretion and goblet cell 
degranulation (Pan and Galligan, 1994, Hoffman et al., 2012). Furthermore, activation of 
mucosal 5-HT4 receptors has been shown to stimulate propulsive motility, decrease 
visceral hypersensitivity, promote epithelial proliferation and promote the integrity of the 
epithelial barrier (Spohn et al., 2016). In the outer layers of the intestines, 5-HT4 agonist 
stimulation has been shown to promote neuronal proliferation and survival, and to 
enhance growth of nerve fibers (Liu et al., 2009, Matsuyoshi et al., 2010, Belkind-Gerson 
et al., 2015) 
The 5-HT4 receptor, has been identified as a potent therapeutic target for 
constipation relief in irritable bowel syndrome (IBS) and chronic constipation, as well as 
pain relief in IBS (Novick et al., 2002, Chey et al., 2008, Tack et al., 2012). Studies from 
our lab have shown that intracolonic administration of the 5-HT4 agonist, tegaserod, 
improves colitis recovery over intraperitoneal administration in experimental models of 
colitis (Spohn et al., 2016).  
This study examined the hypothesis that a luminally restricted 5-HT4 agonist, 
SYR313832Z, would exert protective epithelial actions and restore normal motility 
patterns in murine dextran sodium sulfate induced colitis. We used a recovery paradigm 
to investigate whether treatment of animals with active colitis would accelerate 
recuperation. Outcome measures included recording disease activity index, examining 
levels of fecal lipocalin-2, histological damage scoring, assessing epithelial proliferation, 
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and measuring colonic motility. The measures tested in this study reveal no effect of the 
luminally restricted agonist on colitis. 
 
III. Methods 
Animal Care and Use 
 All experimental protocols were approved by the Institutional Animal Care and 
Use Committee of the University of Vermont. The animals used in this study were 8-10 
week-old male CD-1 IGS mice (Charles River Laboratories, Saint-Constant, QC, 
Canada). Animals were euthanized using isoflurane overdose followed by 
exsanguination.  
 
Experimental Paradigms 
For these studies, the protective epithelial actions of the proprietary, luminally 
restricted 5-HT4 agonist, SRY313832Z (832Z), were assessed in a paradigm modeling 
recovery from induced colitis. 832Z was given to us by Takeda Pharmaceuticals for the 
purposes of this study. Pharmacokinetics analyses by Takeda indicate that 832Z is not 
detectable in the blood serum and it is heavily detected in colonic tissue up to 8 hours 
after gavage administration.  
Colitis was induced by addition of 3% or 4% DSS to the drinking water on days 0 
through 5. On day 5, DSS water was replaced with tap water. Starting on day 5, mice 
received daily administration (gavage or enema) of 832Z, tegaserod (positive control) or 
vehicle for 10 consecutive days (see Table 1 for formulations). Mice were euthanized on 
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day 15, and colon sections taken for histology and immunohistochemistry. To assess 
levels of inflammation and colitis severity the following assays were used: disease 
activity index score, histological damage score, and fecal lipocalin-2 levels. The 
measures of colonic motility included fecal water content, fecal output and bead 
expulsion. Any differences in the paradigm or drug administration protocol are noted in 
the figure legends. 
 
Table 1. Drug and vehicle formulations for 15 day recovery paradigm. 
 
Disease Activity Index 
Disease severity was assessed using a rubric score throughout the course of the 
disease paradigm. This rubric includes the major pathological landmarks of colitis: 
weight loss, stool consistency, and fecal blood. Each symptom is rated on a scale from 0 
to 4; with a score of 4 being the most severe. The exact scoring criteria were adapted 
from Cooper et. al. and is described in Table 2 (Cooper et al., 1993). This score was taken 
every other day through out the experimental paradigm to track the progression of the 
colitis. For the sake of this study, a score of 4-8 is considered moderate colits, whereas a 
score greated than 8 is considered severe colitis.  
 Gavage Enema 
Vehicle 1% Tween80, 0.5% Methyl 
Cellulose in tap water 
1% DMSO in 0.9% saline 
832Z 10 mg/kg 832Z, 1% 
Tween80, 0.5% Methyl 
Cellulose in tap water 
1 or 10 mg/kg 832Z, 1% 
DMSO in 0.9% saline 
Tegaserod N/A 1 mg/kg tegaserod, 1% 
DMSO in 0.9% saline 
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Score Weight Loss Stool Consistency Occult/gross bleeding 
0 None Normal Normal 
1 1-5%   
2 5-10% Loose stool Hemoccult + 
3 10-20%   
4 >20% Diarrhea Gross bleeding 
	  
Table 2. Details of disease activity index rubric. 
	  
Fecal Lipocalin-2 ELISA 
Fecal pellets were collected over the course of the experiment and stored at -20 
degrees Celsius. To prepare samples for the assay, fecal pellets were homogenized in 
0.1% Tween20/PBS at 50 mg/mL, and then centrifuged for 5 minutes at 20,000 x g. 
Supernatant was collected and diluted from 1:5 to 1:6000 depending on the time point of 
the sample. Two dilutions were performed for each sample using the kit-recommended 
diluent (1% BSA in PBS). Lipocalin-2 levels were determined using a solid phase 
sandwich ELISA (Mouse Lipocalin-2/NGAL DuoSet ELISA kit, R&D Systems, 
Minneapolis, MN), and levels compared between the treatment and control groups at all 
time points. Dilutions that presented the most accurate duplicates and that fell within the 
standard curve of the ELISA were used for analysis. 
 
Histological Damage Score 
Histological assessment of tissue damage is a classic method to determine the 
extent of colitis. For this measure, small pieces of distal colon were fixed in 4% PFA and 
0.1M sodium phosphate, paraffin embedded, sectioned, and stained using a hematoxylin 
and eosin (H&E) stain. Sections were blindly scored according to a scoring rubric that is 
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based on the classic histological features of human inflammatory bowel disease 
(Villanacci et al., 2013, Spohn et al., 2016). Briefly, the rubric considers infiltration of 
immune cells, cytoarchitecture, crypt architecture, epithelial integrity and ulcerations. 
Scores were compared between treatment and control groups by an unpaired students t-
test or one-way ANOVA, as appropriate. 
 
Proliferation Assay 
Epithelial cell proliferation was assessed using immunohistological staining for 
the post-mitotic marker Ki-67, a technique that has been used previously to assess 
epithelial proliferation in human and animal models of colitis (Joly et al., 2009, Hoffman 
et al., 2012, Spohn et al., 2016). Paraffin-embedded sections of distal colon (same as used 
for H&E staining), were co-stained for Ki-67 and the nuclear marker DAPI. Within each 
crypt, the ratio of Ki-67+ cells:DAPI+ nuclei was counted. Three crypts were analyzed per 
tissue section, and then averaged to give a percent of Ki-67+ cells per crypt. These 
numbers were compared between groups using an unpaired students t-test. 
 
Colonic Motility 
The bead expulsion assay is an in vivo assay to assess colonic motility. This assay 
has been used previously to assess in vivo colonic motility in DSS colitis (McClain et al., 
2014, Spohn et al., 2016). Briefly, the assay was performed by inserting a glass bead 2 
cm into the rectum of a lightly anesthetized mouse and recording the latency from waking 
of the animal to expulsion of the bead. Bead expulsion data were collected from each 
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mouse before, during and after inflammation (approximately days 0, 5, and 15). This 
technique allowed for an in vivo measurement of colonic motility at multiple time points. 
Expulsion times shorter than 30 seconds and longer than 40 minutes were excluded. 
Expulsion times were either averaged and compared between groups using an unpaired 
students t-test, or normalized to the day 0 expulsion time, averaged and compared 
between groups over time using a two-way ANOVA. 
 
Fecal Output and Water Content  
Fecal output is the measurement of number of fecal pellets produced during one 
hour. To measure fecal water content, all pellets were collected during the fecal output 
assay and immediately placed into closed Eppendorf tubes. At the end of one hour, the 
total wet weight of all pellets was recorded. Pellets were then dried overnight at 50 
degrees Celsius, and the dry weight was obtained the following day. The longer it takes a 
pellet to pass through the colon, the dryer the pellet will be (i.e. more time for water 
absorption leads to lower water content in the feces). Additionally, inflammation of the 
colon affects the absorption and secretion action of the epithelium, and thus inflammation 
of the colon also leads to increased water content. Fecal output and fecal water content 
were assessed over the course of the experimental paradigm, and results were comparted 
between vehicle and treatment groups.  
 
 
 
 
 
	  
38 
Data Analysis 
 Data are shown as mean +/- SEM for n number of animals. All data analysis was 
completed using GraphPad Prism software (version 7.0; GraphPad Software, La Jolla, 
CA). Data sets were examined before analysis to ensure that test assumptions were met 
(variability and n values per group). Significance was determined using unpaired students 
t-test, one-way ANOVA, or two-way ANOVA, with corrections for multiple comparison, 
where appropriate. Statistical significance was defined as P values of less than 0.05. 
 
IV. Results 
Effect of Treatment on Disease Activity  
 Disease activity index (DAI) is an in vivo assay of disease severity that can be 
taken at multiple time points throughout the course of colitis development and recovery. 
It is common practice in the field to utilize such a rubric to understand disease 
progression and recovery (Spohn et al., 2016, Wirtz et al., 2017). We tested whether 
intracolonic treatment of 832Z (10 mg/kg) would improve recovery from colitis, 
decreasing the DAI relative to the DAI of vehicle treated animals. This effect has 
previously been seen with intracolonic administration of tegaserod, was blocked by 
antagonist pre-treatment, and was not seen in 5-HT4 knockout mice (Spohn et al., 2016). 
 In the current study, DAI was assessed approximately every other day over the 
15-day paradigm (3% DSS for 5 days, 10 days treatment). There was no significant effect 
of either treatment (Figure 1A and 1B). Many other iterations of this paradigm were 
performed with different drug delivery methods, different concentrations of drug, and 
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different concentrations of DSS, and similar results were obtained (Supplemental Figures 
1-4). 
 
Effect of treatment on Histological Damage 
 Clinically diagnosis of colitis typically involves histological evaluation of patient 
biopsies to determine the extent of inflammation. In experimental colitis, histological 
evaluation of mucosal architecture and neutrophil infiltration is a common method used 
to determine the extent of disease (Wirtz et al., 2017). Other methods, such as endoscopy, 
allow for longitudinal evaluation of mucosal health; however, evaluation of histological 
damage is the most robust readout. Given previous reports from our lab of improved 
histological damage with the 5-HT4 receptor agonist tegaserod, we tested whether 
histological damage would be alleviated by the 5-HT4 agonist 832Z.  
We found no significant difference in histological damage scores between groups 
(Figure 1C). Many other iterations of this paradigm were performed with different drug 
delivery methods, different concentrations of drug, and different concentrations of DSS, 
and comparable results were obtained (Supplemental Figures 1-4). 
 
Effect of treatment on Epithelial Proliferation 
 Human and experimental colitis is associated with degradation of the epithelial 
barrier. It has previously been shown that treatment with a 5-HT4 agonist promotes 
epithelial proliferation in vitro and in vivo, resulting in improved barrier function and 
improved histological appearance (Spohn et al., 2016). Thus, we expected that 
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intracolonic treatment with the luminally restricted 5-HT4 agonist would result in an 
increase of recently divided epithelial cells.  
 Our results indicate that there is no effect of treatment with 832Z on epithelial 
proliferation (Figure 1D). Many other iterations of this paradigm were performed with 
different drug delivery methods, different concentrations of drug, and different 
concentrations of DSS, and similar results were obtained (Supplemental Figures 1-4). 
 
Effect of treatment on fecal lipocalin-2 levels 
 Recently, lipocalin-2 (Lcn-2), also known as neutrophil gelatinase-associated 
lipocalin in humans, has been identified as a non-invasive and sensitive biomarker of 
intestinal inflammation in TNBS, DSS, and IL-10 knockout experimental colitis 
(Chassaing et al., 2012, Hsieh et al., 2016). Fecal lipocalin levels are correlated with 
disease severity and pro-inflammatory cytokine levels in DSS-induced colitis and 
spontaneous colitis in IL-10 deficient mice (Chassaing et al., 2012). We tested whether 
Lcn-2 levels increased with induction of colitis, and then decreased as mice recovered 
from colitis. Additionally, we tested whether Lcn-2 levels for animals treated with 832Z 
and tegaserod returned to baseline faster than vehicle treated animals. To our knowledge, 
this is the first time lipocalin levels have been tested in CD-1 mice in response to 
induction of DSS colitis, and more importantly, used to assess the efficacy of therapeutic 
administration.  
 We found there was an increase of Lcn-2 levels in response to 3% DSS 
administration, but no return to baseline during the recovery phase of the paradigm 
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(Figure 1E; significant effect of day, p=0.038 by two-way ANOVA). With induction at 
3% DSS, Lcn-2 levels increased to ~10,000 ng/g feces by day 10 post-induction, and 
remained high through day 15. There were no significant differences between vehicle and 
agonist treated groups (Figure 1E). A preliminary study was conducted using 2.5% and 
3% DSS, and assessing Lcn-2 levels in untreated mice out to day 25. By day 10, levels 
rose to ~ 7000 ng/g25, and only dropped to ~1000 ng/g by day 25 (Supplemental Figure 
5; not significant). Many other iterations of this paradigm were performed with different 
drug delivery methods, different concentrations of drug, and different concentrations of 
DSS, and similar results were obtained (Supplemental Figures 1-4). 
 
Effect of treatment on colonic motility 
 It has been established that clinical IBD and experimental colitis models are 
associated with abdominal pain and changes in colonic motility and stool frequency 
(Linden et al., 2004, Hoffman et al., 2011, Vivinus-Nebot et al., 2014, Spohn et al., 
2016). In animal models, it has been shown that colonic motility is decreased in colitis 
and is associated with inflammation induced neuroplasticity (Hoffman et al., 2011, 
Roberts et al., 2013). Additionally, it has been shown that treatment with a 5-HT4 agonist 
rescues this slowing of colonic motility in mice and guinea pigs (Spohn et al., 2016). 
Thus, we tested whether treatment with 832Z affected colitis induced dysmotility.  
 We found no changes in latency of bead expulsion between vehicle and treatment 
groups when colitis was induced with 3% DSS (Figure 1F). Interestingly, we also did not 
see the expected slowing of motility from days zero to five in response to colitis 
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induction. This slowing of motility was noted in one experiment in response to 4% DSS, 
with a significant effect of treatment (Supplemental Figure 1E; significant effect of 
treatment, p=0.0098, by two-way ANOVA). Many other iterations of this paradigm were 
performed with different drug delivery methods, different concentrations of drug, and 
different concentrations of DSS, and similar results to that of 3% colitis induction were 
obtained (Supplemental Figures 1-4). 
 Fecal output and fecal water content were only assessed in the first iteration of 
this study (Supplemental Figures 1F and 1G). This experiment, along with others in our 
lab, revealed that CD-1 mice have relatively high fecal water content at baseline (~60%) 
as compared to C57BL6/J (data not shown). Given this finding, in addition to the fact that 
diarrhea is a primary read out of colitis, we decided to discontinue this assay in the colitis 
models. Additionally, bead expulsion appeared to be a more robust measure of colonic 
motility than fecal output. Therefore, this assay was discontinued as well.  
 
V. Discussion 
 This study tested the hypothesis that luminally restricted 5-HT4 agonists would 
induce protective epithelial actions in DSS-induced experimental colitis. The results of 
this study failed to support the hypothesis. With the conditions that were tested, the 
luminally restricted 5-HT4 agonist did not exert protective effects detectable by our 
outcome measures. Given previous research, these results are surprising and lead us to 
believe that this study may not have involved conditions optimal for activity of the 
luminally restricted agonist 832Z. 
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Based on the results reported here, it appears that 832Z does not exert the same 
protective actions that have previously been published for the 5-HT4 agonist tegaserod 
(Spohn et al., 2016) Theoretically, this compound should stimulate the 5-HT4 receptor 
and initiate the same protective actions – including stimulating epithelial proliferation, 
mucus secretion and propulsive motility. Additionally, pharmacokinetic analysis of 832Z 
performed by Takeda, indicate that this compound is present in colon tissue and the 
colonic lumen up to 8 hours after gavage administration. While this does not indicate that 
the drug is active once it reaches the colon, it does imply that there is compound binding 
to receptors in the wall of the lumen. In our studies, delivery of the compound via enema 
ensured that the compound was reaching mucosal receptors without being altered by 
transit through the stomach and the small intestine. However, even with enema 
administration, no effects of receptor stimulation were seen. This lack of an effect could 
be explained by incorrect dosing of the compound or incompatible vehicle formulation. 
Further studies will be required to test these possibilities. 
An alternative explanation is that the mechanism of protective actions of 
tegaserod are not due to activation of mucosal 5-HT4 receptors. If this were the case, a 
luminally restricted 5-HT4 agonist would be ineffective. It is unknown if epithelial 5-HT4 
receptors are located on the apical or basal side of intestinal epithelial cells. If the 
receptor is located on the basal side of epithelial cells, an agonist would have to be 
present in the lamina propria to stimulate receptor actions. This would require a 
mechanism to transport a luminally delivered compound from the lumen into the lamia 
propria. Under normal conditions, transport mechanisms are predominately expressed in 
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the small intestine, not colonic epithelial cells. However, the transporter protein hPept1 is 
aberrantly expressed in colonic epithelial cells of UC and CD patients, and have a role in 
transporting bacterial di- and tri-peptides across the epithelial barrier (Merlin et al., 
2001). Another possible explanation is that tegaserod can diffuse across the compromised 
epithelial barrier known to occur in experimental colitis, and the luminally restricted 5-
HT4 agonist cannot.  
These explanations, while plausible, are unlikely. Previous results from our lab 
demonstrate that intracolonic administration of tegaserod was significantly more effective 
than systemic administration (IP) in reducing experimental colitis activity. Additionally, 
the effect of intracolonic tegaserod was blocked by intraluminal administration of a 5-
HT4 selective antagonist. These results indicate that luminal 5-HT4 receptor activation is 
necessary to induce the protective actions, and that it is a 5-HT4 receptor specific effect. 
Future investigations involving conditional knockdown of the 5-HT4 receptor in epithelial 
cells might be necessary to confirm the involvement of epithelial receptors in the 
protective actions. 
Tegaserod is also a 5-HT2B receptor antagonist. 5-HT2B receptors are located on 
longitudinal and circular gastrointestinal smooth muscle cells and neurons within the 
myenteric plexus (Engel et al., 1984, Borman et al., 2002). Additionally, tegaserod has 
similar affinity for the 5-HT2B receptor as for the 5-HT4 receptor (Beattie et al., 2004). 
Therefore, it is possible that any effects of tegaserod on motility could have been 
complicated by 5-HT2B antagonism, but it is improbable that 5-HT2B receptor antagonism 
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would interfere with protective epithelial actions. Furthermore, it is unknown the affinity 
of the luminally restricted 5-HT4 agonist for the 5-HT2B receptor. 
It is important to note that there were inconsistencies in the model of experimental 
colitis that was used. We had significant variability in the extent of colitis that was 
induced, and we were not able to reproduce the protective actions of tegaserod (Figure 1; 
Supplemental Figures 3 and 4). A possible explanation for the variability in the colitis 
model is due to the type of DSS used. Previous studies in our lab induced colitis with 
DSS from MP Biomedicals (Solon, OH; molecular weight: 36,000-50,000), while the 
current study used DSS from Affymetrix (Cleveland, OH; molecular weight: 40,000-
50,000). It is known that dosing and the molecular weight of DSS affect the quality and 
severity of inflammation (Kitajima et al., 2000). Initial experiments in this study induced 
colitis with 4% DSS, which resulted in many mice developing severe colitis (histological 
damage scores >8 at day 5). For later studies, we induced colitis with 3% DSS to 
stimulate development of a more moderate colitis (histological damage scores 4-8 at day 
5). However, even with this reduction in colitis severity, we failed to see a recovery effect 
of 832Z or tegaserod.  
It was surprising that we were unable to recapitulate the effects of tegaserod. This 
may be attributed to the inconsistencies in the model; therefore, these findings do not 
overturn the previously reported data by our lab (Spohn et al., 2016). 
Lastly, it is plausible that this particular luminally restricted compound, 832Z, 
does not promote epithelial wound healing. Given that this is the first time 832Z has been 
tested in vivo, it is possible that we are not seeing effects because this drug does not exert 
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an effect on the mechanisms addressed in this study. Other research in our lab does 
demonstrate a prokinetic effect of 832Z administration in naïve animals, and this effect is 
blocked by a 5-HT4 antagonist (data not shown). These results are in line with our 
hypothesis and indicate that the compound is active, and stimulates mucosal 5-HT4 
receptors when administered by gavage or enema.  
While this study revealed no effects of the luminally restricted 5-HT4 agonist 
SYR313832Z, there is need for further study to confirm these findings. This study was 
complicated by inconsistencies in the animal model and a lack of effect of the positive 
control, tegaserod. While it is possible that this compound does not exert protective 
actions in colitis, there is not sufficient evidence to make a definitive conclusion. 
 
 Concluding Remarks 
This study tested the effects of a novel therapeutic agent, a luminally restricted 5-
HT4 agonist, in an in vivo animal model of colitis. The results show that this novel 
compound does not exert protective epithelial actions or prokinetic effects in dextran 
sodium sulfate induced colitis. However, further studies need to be done to assess this 
novel compound with additional assays to make a definitive conclusion.  
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Figure Legend 
Figure 1. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 weeks old. 
Vehicle n=5*. 832Z n=8. Tegaserod n=7. Colitis induced with 3% DSS. Enema treatment 
with vehicle (1% DMSO/0.9% saline), SYR313832Z (10 mg/kg SYR313832Z, 1% 
DMSO/0.9% saline) or tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline). A) 
Disease activity index over the course of the paradigm. There were no significant 
differences in disease activity index (p=0.1598), however there was a significant effect of 
day (p<0.0001) via 2-way ANOVA. B) Disease activity index for day 15. C) Histological 
damage scores (p=0.7545 by one-way ANOVA). D) Percent Epithelial cells Ki67+, 
reported as a ratio of Ki67+ cells:DAPI stained nuclei. Each data point represents one 
animal, as an average of 3 crypts. (p=0.06217 by one-way ANOVA). E) Fecal Lipocalin-
2 levels for days 0, 5, 10 and 15. There is no significant effect of treatment (p=0.7123), 
but there is a significant effect of day (p=0.038) by two-way ANOVA. F) Bead expulsion 
times for Days 0, 5, and 15, reported as percent of day 0 expulsion time. All times are 
calculated as the latency from wake to expulsion, and the normalized to the day 0 
expulsion time. There was no significant effect of treatment (p=0.4298) or day 
(p=0.7280) by two-way ANOVA. *One mouse was euthanized on day 9 due to >30% 
weight loss and lethargy as per protocol. 
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Supplemental Figure 1 
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Figure Legend 
Supplemental Figure 1. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with 
vehicle (0.5% methylcellulose, 50 mM citrate monohydrate in double distilled water, pH 
3.0) or agonist (10 mg/kg SYR3138637, 0.5% methylcellulose, 50 mM citrate 
monohydrate in double distilled water, pH 3.0). A) Disease activity index over the course 
of the paradigm showed no significant effect of treatment (p=0.5103), but there was a 
significant effect of day (p<0.0001) by two-way ANOVA. Mice reached a peak average 
score of ~7, indicating moderate to severe colitis. B) Histological damage scores showed 
no significant differences between groups (p=0.7245 by unpaired t-test). C) Bead 
expulsion times for Days 0, 5, and 14, reported as percent of day 0 expulsion time. All 
times are calculated as the latency from wake to expulsion, and the normalized to the day 
0 expulsion time. Significant effect of treatment by two-way ANOVA (p=.0098). D) 
Percent Epithelial cells Ki67+, reported as a ratio of Ki67+ cells:DAPI stained nuclei. 
Each data point represents one animal, as an average of 3 crypts. There were no 
significant differences between groups (p=0.5644 by unpaired t-test). E) Lcn-2 levels as 
detected by ELISA showed no significant differences between groups (p=0.5264), but 
there as a significant effect of day (p=0.0052) by two-way ANOVA. F) Fecal output 
showed no effect of treatment (p=0.6006), but there was a significant effect of day 
(p=0.0356) by two-way ANOVA. G) Fecal water content demonstrated to effect of 
treatment (p=0.6418), but there was a significant effect of day (p<0.0001) by two-way 
ANOVA. 
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Supplemental Figure 2 
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Figure Legend 
Supplemental Figure 2. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with 
vehicle (1% Tween80/Tap water) or agonist (10 mg/kg SYR313832Z, 1%Tween80/Tap 
water).  A) Disease activity index over the 15-day paradigm demonstrated no effect of 
treatment (p=0.2123), but a significant effect of day (p<0.0001) by two-way ANOVA. B) 
Histological damage scores demonstrated no significant differences between treatment 
(p=0.4011) by an unpaired t-test. C) Percent Epithelial cells Ki67+, reported as a ratio of 
Ki67+ cells:DAPI stained nuclei. Each data point represents one animal, as an average of 
3 crypts. There was no significant difference between groups (p=0.1557) by an unpaired 
t-test. 
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Supplemental Figure 3 
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Figure Legend 
Supplemental Figure 3. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 
weeks old, 5 mice per group. Colitis induced with 4% DSS. Gavage treatment with 
vehicle (1% Tween80/Tap water), agonist (10 mg/kg SYR313832Z, 1% Tween80/Tap 
water) or enema treatment with tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline). 
A) Disease activity index scores over the course of the paradigm. Tegaserod improved 
DAI quicker than oral 832Z or vehicle, as seen by significant difference on days 8 and 10 
(*p<0.05 between Tegaserod and both vehicle and oral 832Z; ψ p<0.05 between 
Tegaserod and oral 832Z; analysis by two-way ANOVA with multiple comparisons, 
Bonferroni corrections). B) Histological damage scores demonstrated no significant 
differences between treatments at day 15 (p=0.7214) by one-way ANOVA. C) Fecal 
Lipocalin-2 levels on days 0, 5, 7 and 15 as detected by ELISA demonstrated no effect of 
treatment (p=0.3208), but a significant effect of day (p=0.0009) by two-way ANOVA. D) 
Raw bead expulsion times, shown as latency from wake to expulsion in seconds 
demonstrate no significant effect of treatment (p=0.4642) or day (p=0.9734) by two-way 
ANOVA. 
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Supplemental Figure 4 
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Figure Legend 
Supplemental Figure 4. Results from a 15-day recovery paradigm. Male CD1 mice, 8-10 
weeks old, 5 mice per group. Colitis induced with 4% DSS. Enema treatment with 
vehicle (1% DMSO/0.9% saline), SYR313832Z (10 mg/kg or 1 mg/kg SYR313832Z, 1% 
DMSO/0.9% saline) or tegaserod (1 mg/kg tegaserod, 1% DMSO/0.9% saline). A) 
Disease activity index scores over the course of the paradigm demonstrated no effect of 
treatment (p=0.6824), but a significant effect of day (p<0.0001) by two-way ANOVA. B) 
Histological damage scores demonstrate no effect of treatment (p=0.9594) on day 15 by 
one-way ANOVA. C) Percent Epithelial cells Ki67+, reported as a ratio of Ki67+ 
cells:DAPI stained nuclei. Each data point represents one animal, as an average of 3 
crypts. There was no significant difference between groups (p=0.1017) by one-way 
ANOVA. D) Bead expulsion times for Days 0, 5, and 15, reported as percent of day 0 
expulsion time. All times are calculated as the latency from wake to expulsion, and the 
normalized to the day 0 expulsion time. There was no significant effect of treatment 
(p=0.1692) or day (p=0.1116) by two-way ANOVA. 
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Figure Legend 
Supplemental Figure 5. Results from a preliminary experiment inducing colitis with 
either 3% or 2.5% DSS and collected fecal samples for Lcn-2 ELISA at days 5, 10, 15, 
20 and 25. CD1 male mice, aged 8 weeks, 3 mice per group. There was no significant 
effect of treatment (=0.4487) or day (p=0.2090) by two-way ANOVA. 
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CHAPTER III: FINAL CONLUSIONS AND FUTURE DIRECTIONS 
 
I. Summary and Conclusions 
 There is a drastic need for novel therapeutic agents for IBD. The current 
therapies, including anti-inflammatory agents, immunosuppressants, and monoclonal 
antibodies, do not serve all patient needs. A unique target for treatment in IBD is the 
epithelial barrier. Compromised barrier function, or “leaky gut”, is a common feature of 
IBD and may even contribute to the pathogenesis. This study aimed to explore mucosal 
5-HT4 receptor activation using a luminally restricted 5-HT4 agonist as a novel 
therapeutic target for IBD and other functional bowel disorders.  
Results from my study reveal that the luminally restricted 5-HT4 agonist failed to 
exert protective effects in DSS induced colitis. These results were surprising and prompt 
the use of other paradigms and techniques to fully reveal the effects of this compound. 
 
II. Future Directions 
 A primary concern of this study was the inconsistencies and variability within the 
colitis model. It is known that induction of DSS colitis is dependent on both the mouse 
strain and the molecular weight of DSS used (Kitajima et al., 2000, Chassaing et al., 
2014). I think it would be beneficial for future studies to utilize a different mouse strain 
or DSS from a different company to explore the protective actions of 832Z. C57BL/6 
mice are another commonly used strain to study DSS colitis, and I think attempting a 
recovery paradigm with this strain would be beneficial. Additionally, other labs have 
shown recovery of fecal lipocalin-2 levels in C57BL/6 mice. Given the lack of return to 
 
 
	  
63 
baseline of fecal lipocalin-2 levels in the CD-1 mice used in this study, it would be 
beneficial to utilize a strain where we know that this biomarker can indicate a reduction 
in inflammation. Furthermore, our lab has demonstrated prokinetic effects of 832Z in 
naïve C57BL/6 mice, but not CD-1 mice. We initially used CD-1 mice for the colitis 
studies based on the previous work in our lab showing protective epithelial actions of 
tegaserod in CD-1 mice (Spohn et al., 2016). However, the CD-1 mice used in this study 
had hemoccult positive stool at baseline, and sometimes soft stool, indicating a slight 
dysregulation of epithelial barrier homeostasis prior to induction of colitis. We were 
unable to identify the cause of these symptoms. C57BL/6 mice concurrently used in our 
lab did not show the same symptoms. Therefore, I think it would be beneficial to test this 
same hypothesis using C57BL/6 mice given that they are healthy at baseline and we have 
seen effects of the compound on gastrointestinal motility. Additionally, I propose using a 
more sensitive disease activity index rubric for the daily disease scoring. A protocol 
update for chemically induced models of colitis included a disease activity index rubric 
with more detailed scoring of stool consistency and fecal blood (see table 3) (Wirtz et al., 
2017). Utilization of this more detailed DAI rubric would take away some of the inherent 
subjectivity of scoring stool consistency.  
Score Weight Loss Stool Consistency Occult/gross bleeding 
0 None Normal Negative hemoccult 
1 1-5% Soft but still formed  
2 5-10% Soft Positive hemoccult 
3 10-20% Very soft; wet Blood traces in stool  
4 >20% Watery diarrhea Gross rectal bleeding 
	  
Table 3. Scoring system for disease activity index from Wirtz et al. (2017) 
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 Given the null results of this study in an in vivo model, I also suggest testing the 
actions of 832Z with in vitro and ex vivo assays that specifically test the effects on barrier 
function and wound healing. It is known that barrier function is disrupted in colitis and 
experimental models of colitis (Stein et al., 1998, Turner, 2009). One of the three primary 
actions of 5-HT4 agonists identified by our lab is improvement of barrier function, 
facilitated by improved wound healing in colitis. Wound healing can be tested in vitro 
using a scratch assay in Caco-2 cells, which specifically measures epithelial migration. 
Caco-2 cells are a human epithelial adenocarcinoma cell line that are frequently used to 
assess properties of intestinal epithelial cells in vitro. Previous reports in our lab 
demonstrate that tegaserod improves closure of the scratch over vehicle control, and that 
this is blocked by co-administration of a 5-HT4 selective antagonist (Spohn et al., 2016). 
Another important component of wound healing is the rate of apoptosis. Reactive oxygen 
species caused by oxidative stress are present in colitis and contribute to epithelial 
apoptosis (Shi et al., 2011, Novak and Mollen, 2015, Spohn et al., 2016). To assess the 
effect of 832Z on reactive oxygen species induced apoptosis, Caco-2 cells are pretreated 
with the compound, exposed to H2O2, and then the percent of cells undergoing apoptosis 
is measured. This question could also be answered in vivo by using a colitis prevention 
paradigm and performing a TUNEL assay on sections of colon after treatment. Barrier 
function or intestinal permeability can be specifically tested ex vivo or in vitro using 
Ussing chamber assays or measuring transepithelial resistance of cultured cells, 
respectively. 
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 This study used one method to assess colonic motility in inflamed mice. There are 
many other assays, some more sensitive than bead expulsion, that can be utilized. Current 
data from our lab indicate prokinetic effects with acute treatment of 832Z in naïve mice 
using measures of whole gastrointestinal transit. Additionally, smaller motor events such 
as colonic migrating motor complexes and slow wave motor events can be video-
captured from ex vivo colon preparations and analyzed to show changes in these more 
minute phenomena. These ex vivo assays can be performed after administration of 
compound to the animal, or with application in the ex vivo bath preparation. Lastly, the 
integrity of the neuromuscular junction can be assessed using intracellular 
electrophysiology to record junction potentials from longitudinal smooth muscle cells.  
 In conclusion, there are many other detection measures that can be utilitzed to 
assess the effects of the luminally restricted 5-HT4 agonist 832Z. While my study did not 
demonstrate any effects of this compound, it was the first study to explore the novel 
therapeutic mechanism of luminally restricted compounds in a model of experimental 
colitis. Additionally, this was the first study to my knowledge assessing fecal lipocalin-2 
levels in CD-1 mice in response to a therapeutic treatment in a model of colitis. These 
results will inform future studies into the protective epithelial actions of this and future 
luminally restricted 5-HT4 agonists.  
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